Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | CHIEF DEVELOPMENT OFFICER | January 02, 2025 | January 06, 2025 |
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Chief Medical Officer | November 07, 2022 | November 09, 2022 |
| MARINUS PHARMACEUTICALS, INC.MRNS · Entity 83359 | Director | February 04, 2022 | February 07, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date January 02, 2025 · Filed January 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 69,057 |
Ending reported balance
After 2025-01-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-01-02 · Grant · Acquired 35,000 · Balance 74,000 F1: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2: Each RSU represents a contingent right to receive one ordinary share. Row 2 · 2025-01-02 · Sale · Disposed 4,943 · Balance 69,057 F3: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2035-01-02 | Direct | 87,000 |
Reported balance
After 2025-01-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-01-02 · Grant · Acquired 87,000 · Balance 87,000 F5: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.
F2: Each RSU represents a contingent right to receive one ordinary share.
F3: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter.
Fulcrum Therapeutics, Inc.
Report date November 07, 2022 · Filed November 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.61 · Expires 2032-11-06 | Direct | 400,000 |
Reported balance
After 2022-11-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-07 · Grant · Acquired 400,000 · Balance 400,000 F1: This option was granted on November 7, 2022 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of November 7, 2022. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on November 7, 2022 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of November 7, 2022. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.
MARINUS PHARMACEUTICALS, INC.
Report date February 04, 2022 · Filed February 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,750 |
Reported balance
After 2022-02-04 transaction · row 1
1 source rowRow 1 · 2022-02-04 · Grant · Acquired 2,750 · Balance 2,750 F1: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on February 4, 2023, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2032-02-04 | Direct | 12,375 |
Reported balance
After 2022-02-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-04 · Grant · Acquired 12,375 · Balance 12,375 F2: The option vests and becomes exercisable in 12 equal monthly installments beginning on March 4, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on February 4, 2023, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer.
F2: The option vests and becomes exercisable in 12 equal monthly installments beginning on March 4, 2022.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MOMENTA PHARMACEUTICALS INC
Report date October 01, 2020 · Filed October 01, 2020
Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 1
1 source rowRow 1 · 2020-10-01 · Disposition to issuer · Disposed 26 · Balance 0 F1: Includes 26 shares acquired under the Issuer's employee stock purchase plan on September 28, 2020. F2: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-01 · Disposition to issuer · Disposed 45,000 · Balance 0 F3: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-01 · Disposition to issuer · Disposed 52,500 · Balance 0 F3: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-01 · Disposition to issuer · Disposed 31,500 · Balance 0 F3: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.20 · Expires 2027-06-20 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-01 · Disposition to issuer · Disposed 23,252 · Balance 0 F4: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-01 · Disposition to issuer · Disposed 15,674 · Balance 0 F4: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.87 · Expires 2030-02-07 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-10-01 · Disposition to issuer · Disposed 3,137 · Balance 0 F4: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.20 · Expires 2027-06-20 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-10-01 · Disposition to issuer · Disposed 36,748 · Balance 0 F4: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-10-01 · Disposition to issuer · Disposed 73,702 · Balance 0 F4: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.87 · Expires 2030-02-07 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-10-01 · Disposition to issuer · Disposed 101,863 · Balance 0 F4: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 26 shares acquired under the Issuer's employee stock purchase plan on September 28, 2020.
F2: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
F3: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
F4: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2020 Filed Jul 1, 2020 21:15 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-080021 · a4.xml · derivative · entry 3 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of MNTA Common Stock. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, 15,000 Restricted Stock Units will vest on June 29, 2021. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, 15,000 Restricted Stock Units will vest on June 29, 2021. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 21:15 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-080021 · a4.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,350 F1 · kind: Shares received pursuant to settlement of Performance Stock Units that were granted on October 17, 2018. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 17:26 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 6,756 | $30.16 | $203,760.96 |
DisclosureSEC source: 0001179110-20-007362 · edgar.xml · nonDerivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,350 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 17:26 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007362 · edgar.xml · derivative · entry 3 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of MNTA Common Stock. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, 15,000 Restricted Stock Units will vest on June 11, 2021. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, 15,000 Restricted Stock Units will vest on June 11, 2021. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 17:26 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007362 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,106 F1 · kind: Shares received pursuant to settlement of Performance Stock Units that were granted on October 17, 2018. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 16:22 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 1,614 | $28.96 | $46,741.44 |
DisclosureSEC source: 0001179110-20-005003 · edgar.xml · nonDerivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,106 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 16:22 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Units · Derivative | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005003 · edgar.xml · derivative · entry 3 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17, 2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 16:22 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 3,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-005003 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17, 2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 17:12 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 7,356 | $28.97 | $213,103.32 |
DisclosureSEC source: 0001179110-20-003307 · edgar.xml · nonDerivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,220 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 17:12 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-003307 · edgar.xml · derivative · entry 3 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of MNTA Common Stock. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the Restricted Stock Units will vest on March 5, 2021. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the Restricted Stock Units will vest on March 5, 2021. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 17:12 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-003307 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,576 F1 · kind: Shares received pursuant to settlement of Performance Stock Units that were granted on October 17, 2018. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 18:55 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 7,689 | $30.03 | $230,900.67 |
DisclosureSEC source: 0001179110-20-001674 · edgar.xml · nonDerivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,576 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 18:55 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001674 · edgar.xml · derivative · entry 3 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 18:55 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-001674 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 19:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $31.87 | $0.00 |
DisclosureSEC source: 0001179110-20-001473 · edgar.xml · derivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2030-02-07 F4 · shares: Represents options granted by the issuer pursuant to the issuer's 2013 Incentive Award Plan, as amended and restated. F5 · derivative.exercise_date: Subject to certain criteria, the stock option will vest and become exercisable with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 19:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001473 · edgar.xml · derivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of MNTA common stock. F2 · shares: Represents restricted stock units granted by the issuer pursuant to the issuer's 2013 Incentive Award Plan, as amended and restated. F3 · derivative.exercise_date: Subject to the officer's continued service, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F3 · derivative.expiration_date: Subject to the officer's continued service, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document |
| January 21, 2020 Filed Jan 22, 2020 17:15 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 1,235 | $30.08 | $37,148.80 |
DisclosureSEC source: 0001179110-20-000700 · edgar.xml · nonDerivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,265 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 17:15 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Units · Derivative | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000700 · edgar.xml · derivative · entry 3 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,500 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17, 2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 17:15 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 3,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-000700 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17, 2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 16:13 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 26,954 | $15.91 | $428,838.14 |
DisclosureSEC source: 0001179110-19-011558 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This transaction was executed in multiple trades at prices ranging from $15.75 to $15.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 18, 2019 Filed Oct 21, 2019 16:29 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 6,318 | $13.83 | $87,377.94 |
DisclosureSEC source: 0001179110-19-011138 · edgar.xml · nonDerivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,954 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 17, 2019 Filed Oct 21, 2019 16:29 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Units · Derivative | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-011138 · edgar.xml · derivative · entry 3 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 14,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17, 2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document |
| October 17, 2019 Filed Oct 21, 2019 16:29 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 14,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-011138 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17, 2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document |
| April 29, 2019 Filed May 1, 2019 16:03 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 2,531 | $15.00 | $37,965.00 |
DisclosureSEC source: 0001179110-19-005356 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,272 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 13, 2019 Filed Apr 16, 2019 17:01 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004990 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,803 Read SEC document |
| April 09, 2019 Filed Apr 11, 2019 16:10 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 8,119 | $15.00 | $121,785.00 |
DisclosureSEC source: 0001179110-19-004909 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,803 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 16:51 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 2,671 | $13.10 | $34,990.10 |
DisclosureSEC source: 0001179110-19-002085 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,922 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 16:26 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 7,742 | $12.70 | $98,323.40 |
DisclosureSEC source: 0001179110-19-001904 · edgar.xml · nonDerivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,593 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 16:26 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001904 · edgar.xml · derivative · entry 3 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 16:26 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-001904 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 16:45 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $12.76 | $0.00 |
DisclosureSEC source: 0001179110-19-001839 · edgar.xml · derivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2029-02-11 F1 · shares: Represents options granted by the issuer pursuant to the issuer's 2013 Incentive Award Plan, as amended and restated. F2 · derivative.exercise_date: The stock option will vest and become exercisable with respect to 32,500 shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. All vesting is subject to Dr. Arroyo's continued service to the Company through the applicable vesting date. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 18:10 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 56,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-012293 · edgar.xml · derivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of MNTA common stock. F2 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F2 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 17:01 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 2,665 | $22.20 | $59,163.00 |
DisclosureSEC source: 0001179110-18-009006 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,335 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 18:04 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002109 · edgar.xml · derivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of MNTA common stock. F2 · derivative.exercise_date: Subject to certain criteria, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date. F2 · derivative.expiration_date: Subject to certain criteria, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 16:26 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $17.20 | $0.00 |
DisclosureSEC source: 0001179110-17-009461 · edgar.xml · derivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-06-20 F2 · shares: Represents options granted by the issuer pursuant to the issuer's 2013 Incentive Award Plan. F3 · derivative.exercise_date: The stock option will vest and become exercisable with respect to 37,500 shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. All vesting is subject to Dr. Arroyo's continued service to the Company through the applicable vesting date. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 16:26 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-009461 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 F1 · kind: Represents 36,000 shares of restricted common stock, $0.0001 par value per share, awarded pursuant to the Company's 2013 Incentive Award Plan, as amended and restated, and subject to a restricted stock agreement to be entered into between the Company and Dr. Arroyo. Pursuant to the restricted stock agreement, the shares of restricted common stock shall vest on the achievement of certain company goals within a specified time period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.